Ensysce Biosciences vs Lipocine
ENSC and LPCN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENSC and LPCN compare
Lipocine is the larger company, worth 1.8 times as much as Ensysce Biosciences ($13.2M against $7.5M).
Ensysce Biosciences grew revenue faster over the last twelve months (−39.3% versus −62.7% for Lipocine).
Lipocine scores higher on the StockData Score (9 against 5 for Ensysce Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENSC | LPCN |
|---|---|---|
| Size and price | ||
| Market cap | $7.5M | $13.2M |
| Share price | $0.384 | $1.60 |
| Change, 1 year | −81.4% | −44.3% |
| Change, 5 years | −100.0% | −91.7% |
| Beta (5Y) | 3.77 | −0.38 |
| Employees | 8 | 14 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 8.4× |
| P/B | – | 0.6× |
| Fair value | – | $2.64 |
| Margin of safety | – | 39.3% |
| Growth | ||
| Revenue growth (TTM) | −39.3% (better) | −62.7% |
| Revenue growth, 5Y average | 5.2% | – |
| Profitability | ||
| Operating margin | −281% (better) | −801% |
| Net margin | – | −755% |
| Return on equity | – | −60.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −791.6× | – |
| Current ratio | 0.70 | 11.48 (better) |
| Altman Z-score | −81.05 | −9.43 (better) |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −123% |
| Shareholder yield | 0.00% (better) | −123% |
| Ownership | ||
| Held by institutions | 4.7% | 36.2% |
| Held by insiders | 6.2% | 9.0% |
| Insider net buying, 12 months | $444K | $596K (better) |
| Short interest, % of float | 0.49% | 4.3% |
Go deeper
- ENSC stock overview
- ENSC income statement
- ENSC valuation and score
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.